Pernille Steen Pettersen  Tuhina Neogi  Karin Magnusson  Hilde Berner Hammer  Till Uhlig  Tore K. Kvien  Ida K. Haugen 《Arthritis u0026amp; Rheumatology》2019,71(7):1070-1077

  相似文献   

    

Jung  Susanne  Libricht  Viktor  Sielker  Sonja  Hanisch  Marcel R.  Schäfer  Edgar  Dammaschke  Till 《Odontology / the Society of the Nippon Dental University》2019,107(1):54-63

Odontology - The aim of this study was to evaluate the biocompatibility of two comparatively new calcium silicate containing sealers (MTA-Fillapex and BioRoot-RCS) with that of two established...  相似文献   

    

Donnermeyer  David  Bürklein  Sebastian  Dammaschke  Till  Schäfer  Edgar 《Odontology / the Society of the Nippon Dental University》2019,107(4):421-436

Odontology - Recently, sealers based on calcium silicates were developed as a new class of endodontic sealers. Inspired by the excellent sealing ability and biocompatibility of calcium...  相似文献   

    

Donnermeyer  David  Vahdat-Pajouh  Noushin  Schäfer  Edgar  Dammaschke  Till 《Odontology / the Society of the Nippon Dental University》2019,107(2):231-236

Odontology - The aim was to evaluate the influence of different irrigation solutions on the push-out bond strength (POBS) of three different sealers (AH Plus, BioRoot RCS, GuttaFlow2). Root canals...  相似文献   

    

Till Markowiak  Nadine Kerner  Reiner Neu MD  Tobias Potzger MD  Christian Großer  Florian Zeman  Hans-Stefan Hofmann MD  Michael Ried MD 《Journal of surgical oncology》2019,120(7):1220-1226

Background and Objectives

Hyperthermic intrathoracic chemotherapy (HITOC) is used for the treatment of malignant pleural tumors. Although HITOC proved to be safe, postoperative renal failure due to nephrotoxicity of intrapleural cisplatin remains a concern.

Methods

This single-center study was performed retrospectively in patients who underwent pleural tumor resection and HITOC between September 2008 and December 2018.

Results

A total of 84 patients (female n = 33; 39.3%) with malignant pleural tumors underwent surgical cytoreduction with subsequent HITOC (60 minutes; 42°C). During the study period, we gradually increased the dosage of cisplatin (100–150 mg/m² BSA n = 36; 175 mg/m² BSA n = 2) and finally added doxorubicin (cisplatin 175 mg/m² BSA/doxorubicin 65 mg; n = 46). All patients had perioperative fluid balancing. The last 54 (64.3%) patients also received perioperative cytoprotection. Overall 29 patients (34.5%) experienced renal insufficiency. Despite higher cisplatin concentrations, patients with cytoprotection showed significantly lower postoperative serum creatinine levels after 1 week (P = .006) and at discharge (P = .020). Also, they showed less intermediate and severe renal insufficiencies (5.6% vs 13.3%).

Conclusions

Adequate perioperative fluid management and cytoprotection seem to be effective in protecting renal function. This allows the administration of higher intracavitary cisplatin doses without raising the rate of renal insufficiencies.  相似文献   

    

Till Wüstemann  Uwe Haberkorn  John Babich  Walter Mier 《Medicinal research reviews》2019,39(1):40-69

The high incidence rates of prostate cancer (PCa) raise demand for improved therapeutic strategies. Prostate tumors specifically express the prostate-specific membrane antigen (PSMA), a membrane-bound protease. As PSMA is highly overexpressed on malignant prostate tumor cells and as its expression rate correlates with the aggressiveness of the disease, this tumor-associated biomarker provides the possibility to develop new strategies for diagnostics and therapy of PCa. Major advances have been made in PSMA targeting, ranging from immunotherapeutic approaches to therapeutic small molecules. This review elaborates the diversity of PSMA targeting agents while focusing on the radioactively labeled tracers for diagnosis and endoradiotherapy. A variety of radionuclides have been shown to either enable precise diagnosis or efficiently treat the tumor with minimal effects to nontargeted organs. Most small molecules with affinity for PSMA are based on either a phosphonate or a urea-based binding motif. Based on these pharmacophores, major effort has been made to identify modifications to achieve ideal pharmacokinetics while retaining the specific targeting of the PSMA binding pocket. Several tracers have now shown excellent clinical usability in particular for molecular imaging and therapy as proven by the efficiency of theranostic approaches in current studies. The archetypal expression profile of PSMA may be exploited for the treatment with alpha emitters to break radioresistance and thus to bring the power of systemic therapy to higher levels.  相似文献   

    

Vishal Luther MRCP  Nuno Cortez‐Dias PhD  Luís Carpinteiro MD  João de Sousa MD  Richard Balasubramaniam MD  Sharad Agarwal MD  David Farwell MD  Mark Sopher FRCP  Girish Babu MD  Richard Till MRCP  Nikki Jones MSc  Stuart Tan MD  Anthony Chow PhD  FRCP  Martin Lowe FRCP  Jem Lane PhD  MRCP  Naveen Pappachan BSc  Nicholas Linton PhD  MRCP  Prapa Kanagaratnam PhD  FRCP 《Journal of cardiovascular electrophysiology》2017,28(11):1285-1294

  相似文献   

    

Christian Vollmer  Andreas P. M. Weber  Martin Wallenfang  Till Hoffmann  Tabea Mettler‐Altmann  Richard Truse  Inge Bauer  Olaf Picker  Alexander M. Mathes 《Microcirculation (New York, N.Y. : 1994)》2017,24(4)

  相似文献   

    

Julie C. Nienstedt  Alexander Gröbe  Till Clauditz  Ronald Simon  Adrian Muenscher  Rainald Knecht  Guido Sauter  Christoph Moebius  Marco Blessmann  Max Heiland  Christina Pflug 《Journal of oral pathology & medicine》2017,46(10):986-990

  相似文献   

    

Till A. Dembek  Paul Reker MD  Veerle Visser‐Vandewalle MD  Jochen Wirths MD  Harald Treuer PhD  Martin Klehr MD  Jan Roediger  Haidar S. Dafsari MD  Michael T. Barbe MD  Lars Timmermann MD 《Movement disorders》2017,32(10):1380-1388

  相似文献